TacticScaleWhat Chengdu Kanghua Biological Products (康华生物) Does & How It Makes Money (300841.SZ)
Updated October 2026 · reflects Chengdu Kanghua Biological Products's latest reported financials
Chinese vaccine maker focused on rabies and meningococcal vaccines. The company earns revenue by manufacturing human vaccines and selling them to disease-control and vaccination channels in China, with the rabies vaccine as its core product.
How Chengdu Kanghua Biological Products makes money
The company earns revenue by manufacturing human vaccines and selling them to disease-control and vaccination channels in China, with the rabies vaccine as its core product.
What Chengdu Kanghua Biological Products does
Chengdu Kanghua Biological Products is a Chinese biotech company, founded in 2004 and based in Chengdu, that researches, develops and sells biological products, mainly human vaccines. Its product line centers on a freeze-dried human rabies vaccine and also includes an ACYW135 meningococcal polysaccharide vaccine. Because it sells only a few products, the company's results depend heavily on demand for rabies vaccination in China, alongside a secondary contribution from meningococcal vaccines.
Products & services
- Freeze-dried human rabies vaccine
- ACYW135 meningococcal polysaccharide vaccine
康华生物是做什么的？
成都康华生物制品股份有限公司成立于2004年，总部位于四川成都，从事生物制品的研发、生产和经营，以人用疫苗为主。核心产品是冻干人用狂犬病疫苗，另有ACYW135群脑膜炎球菌多糖疫苗。 公司产品线比较集中，经营情况在很大程度上取决于国内狂犬病疫苗的需求，流脑疫苗是补充性的业务。
What is Chengdu Kanghua Biological Products worth?
On an owner-earnings DCF, Chengdu Kanghua Biological Products's most-likely value is about ¥54 versus a recent price near ¥53 (1% below fair value). But TacticScale only calls a stock undervalued when the price sits below its conservative no-growth floor (~¥26) with a margin of safety — so the honest verdict here is “Fairly priced — no edge.” Fair value earns its keep only at the extremes, not in the wide middle.
Price sits in the normal range — fair value isn't actionable here; it earns its keep only when price drops below the no-growth floor, or runs to roughly double the optimistic case.
Analysis, not advice. Fair value is a margin-of-safety estimate from a deterministic owner-earnings DCF, not a price target or recommendation. See the full breakdown →
Related companies
Shenzhen Kangtai Biological Products (300601.SZ) · Hualan Biological Vaccine (301207.SZ) · Chongqing Zhifei Biological Products (300122.SZ) · Chengdu Kanghong Pharmaceutical (002773.SZ) · Hualan Biological Engineering (002007.SZ)